Clin Osteol 2018; 23(1): 9-17

Secondary osteoporosis in patients with malignanciesReview articles

Špániková Beata
Osteocentrum pre onkologické diagnózy, interná a praktická ambulancia, Onkologický ústav sv.

Continual improvement of antineoplastic therapy and early diagnosis of malignancies -⁠ especially in breast and prostate cancer cause better survival but it can caused late toxicity. Estrogens have a dominant position in bone turnover. Using inhibitors of aromatase cause blockade of extragonadal synthesis of estrogens. Also androgen deprivation therapy block production of androgens in men with prostate cancer. Chemotherapy and cancer cells by themselves can caused lowering of BMD (bone mineral density) also and low BMD correlate with low traumatic fractures. These fractures, especially those of hip and spine not only reduce the quality of life, but can reduce survival as well. That is the reason why we need to think about osteoporosis, malignancy, breast cancer, prostate cancer, prevention and treatment of secondary osteoporosis it, we need to make some preventive measures, we need to try to make the diagnosis as soon as possible, and we need to treat osteoporosis when it appears.


Key words:
breast cancer -⁠ malignancy -⁠ osteoporosis -⁠ prevention and treatment of secondary osteoporosis -⁠ prostate cancer
Received 6. 8. 2018
Accepted 28. 8. 2018

Published: June 11, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špániková B. Secondary osteoporosis in patients with malignancies. Clinical Osteology. 2018;23(1):9-17.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Coleman RE, Abrahamsson PA, Hadji P (eds). Handbook of cancer-related Bone Diseases. BioScientifica: Bristol 2010 : 91-131. ISBN 13 : 978-1-901978-28-5. ISBN 10 : 1-901978-28-1
    2. Hadji P, Aapro MS, Body JJ et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 2017; 7 : 1-12. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbo.2017.03.001>. Go to original source...
    3. Bartl R, Frisxh B et al. Osteoporosis. Diagnosis, prevention, therapy. 2nd ed. Springer-Verlag: 2009. ISBN 978-3540795261. Go to original source...
    4. Marcus R, Bouxsein ML. The Nature od Osteoporosis. In: Marcus R, Feldman D, Nelson D et al. Osteoporosis. 3rd ed. Academic Press: Oxford 2007. ISBN 9780123705440. Go to original source...
    5. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemoterapy is aasociated with rapid bone loss in women with early-stage breast cancer. J Clin Onkol 2001; 19(14): 3306-3316. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2001.19.14.3306>. Go to original source...
    6. DeVita VT, Lawrence TS, Rosenberg SA (Eds). Cancer: Principles & Practice of Oncology: Primer of the Molecular Biology of Cancer. 2nd Ed. Philadelphia, PA, Wolters Kluwer Health/Lippincott, Williams, and Wilkins 2015. ISBN-13 : 978-1496310637. ISBN-10 : 1496310632
    7. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Aone or in Combination) trial after completed 5 years adjuvant treatment for breast cancer. Lancet 2005; 365(9453): 60-62. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(04)17666-6>. Go to original source...
    8. Coleman RE. Effect of Anastrozol on bone mineral density: 5-years results from the " Arimidex", Tamoxifen, alone or in combination (ATAC) trial. J Clin Oncol 2006; 24(18 Suppl): 511. Dostupné z DOI: <http://dx.doi.org/10.1200/jco.2006.24.18_suppl.511>. Go to original source...
    9. Špánik S, Špániková B. Bone mineral density in early breast cancer patients. Bratisl Lek Listy 2010; 111(1): 27-32.
    10. Špániková B, Špánik S. Studies of Osteoporosis in Cancer Patients in Slovakia -⁠ Experience from single Institute. In: Dionyssiotis Y. Osteoporosis. Intech: Rijeka (Croatia) 2012. ISBN 978-953-51-0026-3. Dostupné z DOI: <http://dx.doi.org/10.5772/29828>. Go to original source...
    11. Markopoulos C, Tzoracoleftherakis E, Koukouras D et al. Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. J CancerRes Clin Oncol 2012; 138(9): 1569-1577. Dostupné z DOI: <http://dx.doi.org/10.1007/s00432-012-1233-z>. Go to original source...
    12. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352(2): 154-164. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa041943>. Go to original source...
    13. Ness RA, Miller DD, Li W. The role of vitamin D in cancer prevention. Chin J Nat Med 2015; 13(7): 481-497. Dostupné z DOI: <http://dx.doi.org/10.1016/S1875-5364(15)30043-1>. Go to original source...
    14. [Early Breast Cancer Trialists' Collaborative Group (EBCTCG)]. Adjuvant bisfosfonate treatment in early breast cancer: metaanalyses of individual patient data from randomised trials. Lancet 2015; 386(10001): 1353-1361. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(15)60908-4>. Erratum in Lancet 2016; 387(10013): 30. Go to original source...
    15. Gnant M. Denosumab and fracture risk in women with breast cancer. Lancet 2015; 386(10008): 2057-2058. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(15)00975-7>. Go to original source...
    16. Planas Morin J, Celma Domenech A, Placer Santos J et al. Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. Rheumatol Int 2014; 34(10): 1419-1425. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296-014-2977-3>. Go to original source...
    17. Popp AW, Zysset K, Lippuner K. Rebound associated vertebral fractures after disscontinuation of denosumab from clinic and biomechanics. Osteoporos Int 2016; 27(5): 1917-1921. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-015-3458-6>. Go to original source...
    18. Kanis JA. Pathogenesis of osteoporosis and fracture. In: Kanis JA (ed). Osteoporosis. Blackwell Healthcare Communications; London 1997 : 22-55.
    19. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21(8): 1215-1223.20. Maillefert JF, Sibilia J, Michel F et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161(4): 1219-1222.21. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9(9): 840-849. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.